Irvine, CA – According to filings with the U.S. Securities and Exchange Commission, AiVita Biomedical is raising $84,999,990.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Hans Keirstead played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AiVita Biomedical
AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

To learn more about AiVita Biomedical, visit http://www.aivitabiomedical.com/

Contact:
Hans Keirstead, Chief Executive Officer
949-872-2555
hans@aivitabiomedical.com
https://www.linkedin.com/in/hanskeirstead/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved